Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
12/2003
12/18/2003WO2003097052A3 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
12/18/2003WO2003087087A3 Heterocyclic compounds and their use as modulators of p38 map kinase
12/18/2003WO2003082817A3 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
12/18/2003WO2003082192A3 Certain pharmaceutically useful substituted aminoalkyl heterocycles
12/18/2003WO2003074500A3 N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
12/18/2003WO2003070701B1 Syntheses of quinazolinones
12/18/2003WO2003066630A3 Quinolinone derivatives for treating cell proliferation related disorders
12/18/2003WO2003057911A3 Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy
12/18/2003WO2003051917A3 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
12/18/2003WO2003045363A3 Treatment of th2 dominated immunological disease states with progesterone receptor antagonists
12/18/2003WO2003045362A3 Treatment of th1 dominated immunological disease states with non-endogenous gestagen compounds
12/18/2003WO2003044021A3 Substituted indolizine-like compounds and methods of use
12/18/2003WO2003039440A3 Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
12/18/2003WO2003030885A3 Modulation of the adventitial tool-like receptor
12/18/2003WO2003029437A3 Secreted proteins
12/18/2003WO2003025149A3 Cell populations which co-express cd49c and cd90
12/18/2003WO2003011263A3 Use of a lactate salt for the treatment and prophylaxis of atherosclerosis
12/18/2003WO2003006045A3 Cxcl10 treatment of secondary tissue degeneration
12/18/2003WO2003000864A8 Nucleic acid-associated proteins
12/18/2003WO2002100899A3 Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
12/18/2003WO2002092781A3 Peptide compounds for counteracting reactive oxygen species and free radicals
12/18/2003WO2002090375A3 Liver x receptor agonists
12/18/2003WO2002081668A3 Desaturase genes and uses thereof
12/18/2003WO2002081627A3 Methods of screening and using inhibitors of angiogenesis
12/18/2003WO2002079456B1 A method for the preparation of immunologically inert amniotic membranes
12/18/2003WO2002060871A8 Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor
12/18/2003WO2002047716A3 Chronic treatment regimen using glucagon-like insulinotropic peptides
12/18/2003WO2002038561A8 Indolylmaleimide derivatives as protein kinase c inhibitors
12/18/2003WO2002032435A9 A composition including a platelet activating factor inhibitor and an antioxidant which interferes with the arachidonic acid cascade
12/18/2003WO2002017878A8 Lung surfactant compositions with dynamic swelling behaviour
12/18/2003WO2002014536A9 Odulating multiple lineage kinase proteins
12/18/2003WO2002007678A3 Mu-conopeptides
12/18/2003US20030232990 For therapy of arteriosclerosis and dyslipidaemias
12/18/2003US20030232986 Inhibitors of caspases
12/18/2003US20030232889 For therapy of cancer, restenosis, psoriasis, autoimmune disease, atherosclerosis, osteoarthritis, rheumatoid arthritis, heart failure, chronic pain, and neuropathic pain
12/18/2003US20030232887 Preparation and use of a stable formulation of allosteric effector compounds
12/18/2003US20030232884 New pharmaceutical formulation
12/18/2003US20030232877 1,3-Bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
12/18/2003US20030232875 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
12/18/2003US20030232869 N3 alkylated benzimidazole derivatives as MEK inhibitors
12/18/2003US20030232868 Cyclic carboxylic acids as integrin antagonists
12/18/2003US20030232865 1,4-Benzofused urea compounds useful in treating cytokine mediated diseases
12/18/2003US20030232864 Novel Compounds and compositions as protease inhibitors
12/18/2003US20030232859 Antiinflammatory agents; for treatment of rheumatoid arthritis and multiple sclerosis
12/18/2003US20030232849 N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
12/18/2003US20030232848 Pyrazole compositions
12/18/2003US20030232846 Caspase inhibitors and uses thereof
12/18/2003US20030232845 Enzyme hydrolase inhibitors such as 1-ethyl-3,7-dihydro-8-((1 R,2R)-(hydroxycyclopentyl)amino)-3-(2-hydroxyethyl)-7-((3-bromo-4 -methoxyphenyl)methyl)-1H-Purine-2,6-dione, used for physiological effects
12/18/2003US20030232841 Amides such as 5-(2-(4-methylpiperazin-1-yl)-phenyl)-furan-2-carboxylic acid 4-chlorobenzylamide, used as antidepressants and for prophylaxis of headaches
12/18/2003US20030232838 6-phenylpyrrolopyrimidinedione derivatives
12/18/2003US20030232831 Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
12/18/2003US20030232828 1-(aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
12/18/2003US20030232823 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof
12/18/2003US20030232813 Novel amino substituted pyrimidinone derivatives
12/18/2003US20030232809 Preventing or treating acute myocardial infarction, unstable angina and peripheral artery occlusion
12/18/2003US20030232806 Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them
12/18/2003US20030232797 Useful as immunomodulating and antiinflammatory compounds and in treatment of cardiovascular disease and cancer
12/18/2003US20030232796 Nanoparticulate polycosanol formulations & novel polycosanol combinations
12/18/2003US20030232790 Dihydro-2h-napthalene-1-one inhibitors of ras farnesyl transferase
12/18/2003US20030232788 Inhibitors of interleukin-1 beta converting enzyme and related proteases
12/18/2003US20030232783 Partial and full agonists of A1 adenosine receptors
12/18/2003US20030232763 Reducing blood glucose concentrations, weight loss, and treating diseases and conditions mediated by the cyclooxygenase-2 and 5-lipoxygenase enzymes; an enzyme inhibitors
12/18/2003US20030232752 Proliferated cell lines and uses thereof
12/18/2003US20030232741 Methods of treatment of glaucoma and other conditions mediated by NOS-2 expression via inhibition of the EGFR pathway
12/18/2003US20030232739 Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist
12/18/2003US20030232430 Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
12/18/2003US20030232349 Nucleic acid and amino acid sequences of proteases and the use of these sequences in the diagnosis and treatment of gastrointestinal, cardiovascular, autoimmune/inflammatory, cell proliferative, and neurological disorders
12/18/2003US20030232118 Beverages containing plant sterols
12/18/2003US20030232099 Powder and an extract of lotus root joints; improves insulin resistance, for diabetes, obesity, hyperlipidemia, hypertension, thrombosis, Alzheimer's disease and senility
12/18/2003US20030232073 Enhanced drug delivery in transdermal systems
12/18/2003US20030232053 Administering to treat rheumatoid arthritis, cancer, restenosis
12/18/2003US20030230478 Process for the preparation of 1,4 - dihydropyridines and novel 1,4-dihydropyridines useful as therapeutic agents
12/18/2003DE10215316C1 Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer Quinoline and isoquinoline derivatives, to a pharmaceutical agent and their use as anti-inflammatory agents
12/18/2003CA2497609A1 Non-peptidic brs-3 agonists
12/18/2003CA2493890A1 Methods for using adamts-12, an integrin and metalloprotease with thrombospondin motifs
12/18/2003CA2490357A1 Gene therapeutic for cerebrovascular disorders
12/18/2003CA2490037A1 Galactosyl isomalt, a method for producing it and its use
12/18/2003CA2489282A1 Medical device for intra-lumenal delivery of pharmaceutical agents
12/18/2003CA2489083A1 Method for identifying agonists or antagonists for the g-protein coupled mas-like 1 receptor
12/18/2003CA2488883A1 Method for identifying agonists or antagonists for the gpr45-like/gpr63 receptor
12/18/2003CA2488798A1 Substituted pyrrolines as kinase inhibitors
12/18/2003CA2488618A1 Novel derivatives of androstane and androstene with ascorbic acid and use thereof in treating or preventing various conditions, diseases, and disorders
12/18/2003CA2488617A1 Nanoparticulate sterol formulations and sterol combinations
12/18/2003CA2488613A1 Novel formate salt of o-desmethyl-venlafaxine
12/18/2003CA2488609A1 A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system
12/18/2003CA2488602A1 Substituted pyrrolines as kinase inhibitors
12/18/2003CA2488567A1 (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
12/18/2003CA2488558A1 Prevention and reduction of blood loss
12/18/2003CA2488498A1 Nanoparticulate polycosanol formulations and novel polycosanol combinations
12/18/2003CA2488497A1 Neuroprotective synergy of erythropoietin and insulin-like growth factor
12/18/2003CA2488403A1 Pharmaceutical formulation
12/18/2003CA2488402A1 Pyrazole-derivatives as p38 kinase inhibitors
12/18/2003CA2488356A1 Novel therapeutic use of polypodium extracts
12/18/2003CA2488346A1 Methods and compositions for the repair and/or regeneration of damaged myocardium
12/18/2003CA2488227A1 Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
12/18/2003CA2488193A1 Inhibitors of the gpib -vwf interaction, their preparation and use
12/18/2003CA2488108A1 Liquid formulation of decitabine and use of the same
12/18/2003CA2487924A1 Use of corticotroph-derived glycoprotein hormone to treat inflammation and potentiate glucocorticoid action
12/18/2003CA2487838A1 Methods and compounds for inhibiting the cytokine or biological activity of mif
12/18/2003CA2487418A1 Metalloproteinase inhibitors
1 ... 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 ... 1595